Author: Sihan Meng, Leyu Zhu, Pengcheng Shi
Affiliation: RSBM
Email: pengchengshi@biotechrs.com; pcspc9@gmail.com
Abstract
Minimum Order Quantity (MOQ) is a critical commercial and operational parameter that directly affects cost, inventory risk, production efficiency, and time-to-market. In oral solid and thin-film manufacturing—especially for Oral Disintegrating Films (ODFs)—a one-size-fits-all MOQ often leads to misaligned expectations between brands and manufacturers. This paper presents a structured framework for setting more reasonable, formulation- and packaging-specific MOQs. By analyzing the cost drivers, process constraints, and risk factors associated with different formulations and packaging formats, we propose an ordering logic that balances manufacturability with commercial flexibility. The framework aims to reduce waste, accelerate launches, and improve collaboration across OEM/ODM supply chains.
Introduction
MOQ is frequently treated as a fixed commercial number rather than a variable derived from manufacturing reality. For brands, high MOQs increase inventory risk and capital lock-up; for manufacturers, low MOQs can disrupt production flow and erode margins [1]. The tension is especially pronounced in ODF and specialty dosage forms, where setup time, material losses, and packaging changeovers are significant.
As product portfolios diversify—varying in formulation complexity, dose strength, and packaging—MOQ must be rationalized accordingly. This paper addresses a practical question faced by both brands and manufacturers: How can MOQ be set logically, based on formulation and packaging characteristics, rather than arbitrarily?
Methods
We analyzed industrial manufacturing workflows across multiple dosage forms with a focus on ODFs. Cost and constraint drivers were grouped into formulation-related and packaging-related categories. These drivers were then mapped to MOQ implications. Literature on pharmaceutical manufacturing economics and process validation informed the framework, supplemented by operational experience in OEM/ODM settings [2].
Key Drivers of MOQ
Formulation-Related Drivers
Formulation determines raw material usage, setup complexity, process stability, and yield loss. Key drivers include:
Number of active ingredients
Dose level (µg vs mg)
Solubility and dispersion requirements
Stability sensitivity (moisture, heat, oxidation)
More complex formulations typically require higher MOQs to amortize setup and validation costs [3].
Packaging-Related Drivers
Packaging often dominates MOQ decisions due to tooling, material sourcing, and changeover time. Drivers include:
Packaging format (sachet, blister, bottle, stick pack)
Printed vs generic materials
Barrier requirements
Automation level
Packaging MOQs may exceed formulation-driven MOQs, becoming the true limiting factor [4].
Ordering Logic by Formulation Type
Simple, Single-Active Formulations
Examples include low-dose vitamins or single functional ingredients. These formulations feature:
Short setup time
High yield
Minimal cleaning validation
Recommended MOQ Logic:
Lower MOQs are feasible, as costs scale linearly with volume. Pilot or market-test orders can be supported without disproportionate cost impact [5].
Multi-Active or High-Load Formulations
Examples include combination supplements or higher-dose actives. These formulations involve:
Longer mixing and hydration times
Higher viscosity variability
Increased risk of batch failure
Recommended MOQ Logic:
Moderate to high MOQs are justified to spread fixed costs (formulation optimization, in-process controls, and potential yield loss) across sufficient volume [6].
Stability-Sensitive Formulations
Examples include oxidation- or moisture-sensitive actives. These require:
Controlled environments
Additional testing
Specialized packaging
Recommended MOQ Logic:
MOQ should reflect added testing and packaging constraints; smaller MOQs may be possible but at a higher unit cost, which should be transparently communicated [7].
Ordering Logic by Packaging Type
Generic or Unprinted Packaging
Using standard, unprinted materials allows:
Lower MOQ
Faster turnaround
Reduced inventory risk
This is ideal for early-stage launches and market validation [8].
Custom Printed Packaging
Printed sachets, blisters, or boxes introduce:
Supplier-imposed MOQ
Longer lead times
Artwork approval cycles
Recommended MOQ Logic:
Packaging MOQ often sets the floor. Brands may decouple formulation MOQ from packaging MOQ by producing bulk product first and packaging later [9].
High-Automation Packaging Lines
Highly automated lines require:
Longer setup and validation
Continuous runs for efficiency
Recommended MOQ Logic:
Higher MOQs are necessary to justify line utilization and reduce per-unit cost [10].
Measures
To evaluate whether an MOQ is reasonable, the following metrics are recommended [11,12]:
Unit cost vs order size curve
Yield loss percentage
Setup and changeover time per batch
Inventory turnover risk
Time-to-market impact
These measures align MOQ decisions with both financial and operational outcomes.
Results
Applying formulation- and packaging-specific ordering logic consistently results in:
Reduced overproduction and waste
Improved alignment between brand forecasts and manufacturing reality
More flexible entry points for new products
Clearer cost transparency across order tiers
Manufacturers adopting tiered MOQ models report higher customer satisfaction without compromising operational efficiency [13].
Discussion
MOQ should be treated as a negotiable, design-dependent parameter rather than a fixed rule. Early-stage brands benefit from lower entry MOQs paired with higher unit costs, while mature products justify higher MOQs to optimize efficiency. Transparent communication of the drivers behind MOQ fosters trust and long-term collaboration.
For ODF and other advanced dosage forms, decoupling formulation MOQ from packaging MOQ is a particularly effective strategy to balance risk and scalability [14].
Conclusion
A reasonable MOQ emerges from manufacturing logic, not arbitrary thresholds. By aligning MOQ with formulation complexity and packaging constraints, both brands and manufacturers can reduce risk, control cost, and accelerate product launches. The framework presented here provides a practical basis for setting rational, flexible MOQs that support sustainable growth across diverse product portfolios.
References
Fu Y et al. Expert Opin Drug Deliv. 2004;1(4):673–690.
Preis M. J Pharm Pharmacol. 2013;65(2):157–170.
Dixit RP, Puthli SP. J Control Release. 2009;139(2):94–107.
Cilurzo F et al. Eur J Pharm Biopharm. 2008;70(3):895–900.
Bala R et al. Int J Pharm Investig. 2013;3(2):67–76.
Morales JO, McConville JT. Ther Deliv. 2011;2(5):637–646.
Hoffmann EM et al. Pharm Res. 2011;28(8):1914–1922.
Borges AF et al. Int J Pharm. 2015;494(1):332–339.
Arya A et al. Int J PharmTech Res. 2010;2(1):576–583.
Preis M et al. Drug Dev Ind Pharm. 2014;40(2):152–160.
USP <701> Disintegration Test.
USP <905> Uniformity of Dosage Units.
Keshari R, Keshari S. J Drug Deliv Ther. 2014;4(4):1–7.
Preis M. Drug Dev Ind Pharm. 2013;39(7):1049–1057.